Accueil>>Signaling Pathways>> Microbiology & Virology>> HIV>>D77

D77

Catalog No.GC33982

Le D77 est un inhibiteur anti-VIH-1 ciblant l'interaction entre l'intégrase et le LEDGF/p75 cellulaire. D77 inhibe la réplication du VIH-1 (IIIB) par une valeur EC50 de 23,8 μg/ml dans la cellule MT-4 (5,03 μg/ml pour les cellules C8166).

Products are for research use only. Not for human use. We do not sell to patients.

D77 Chemical Structure

Cas No.: 497836-10-9

Taille Prix Stock Qté
2mg
214,00 $US
En stock
5mg
321,00 $US
En stock
10mg
459,00 $US
En stock
50mg
1 379,00 $US
En stock
100mg
1 930,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

D77 is anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. D77 inhibits HIV-1(IIIB) replication by EC50 value of 23.8 μg/ml in MT-4 cell (5.03 μg/ml for C8166 cells).IC50 value: 23.8 μg/ml (EC50, in MT-4 cell ), 5.03 μg/ml (EC50, in C8166 cell)Target: HIV-1in vitro: D77 exhibits a highly specific binding affinity to HIV-1 integrase catalytic core domain.D77 induces a dramatic concentration-dependent decrease of α-galactosidase activity compared to the D77-untreated cells. D77 reveals a significant inhibition activity against the interaction of IN with IBD.

[1]. Du L, et al. D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. Biochem Biophys Res Commun. 2008 Oct 10;375(1):139-144.

Avis

Review for D77

Average Rating: 5 ★★★★★ (Based on Reviews and 35 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for D77

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.